dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pernas, Sonia |
dc.contributor.author | Villagrasa, Patricia |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Scaltriti, Maurizio |
dc.contributor.author | Rodon Ahnert, Jordi |
dc.contributor.author | Burgués, Octavio |
dc.contributor.author | Nuciforo, Paolo Giovanni |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.date.accessioned | 2022-05-13T06:46:13Z |
dc.date.available | 2022-05-13T06:46:13Z |
dc.date.issued | 2021-11-04 |
dc.identifier.citation | Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, et al. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/7527 |
dc.description | Anàlisi de seqüències d'ADN; Subtipus PAM50; Genètica molecular |
dc.description.sponsorship | This study was supported by a grant from Novartis. This study was funded, in part, by the project PI 15/01508, integrated in the Plan Estatal I+D+I and co-funded by Instituto de Salud Carlos III - Subdirección General de Evaluación and European Regional Development Fund (ERDF) (to EC) and by a grant from Mutua Madrileña Foundation (to EC). The decisions and responsibilities of this study were all under the sponsor: SOLTI Breast Cancer Research Group. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Mama - Càncer - Aspectes moleculars |
dc.subject | Farmacologia molecular |
dc.subject.mesh | Molecular Targeted Therapy |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Genomics |
dc.title | First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2021.744112 |
dc.subject.decs | terapia molecular selectiva |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | genómica |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2021.744112 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pernas S] Catalan Institute of Oncology (ICO)- Institut d’Investigació Biomédica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Villagrasa P] SOLTI Breast Cancer Research Group, Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Scaltriti M] Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY, United States. [Rodón J] Oncology Department, Monroe Dunaway (MD) Anderson Cancer Center, Houston, TX, United States. Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Burgués O] Pathology Department, Hospital Clínico Universitario Valencia, Valencia, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Oliveira M] SOLTI Breast Cancer Research Group, Barcelona, Spain. Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34804931 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |